{"id":745306,"date":"2016-11-07T07:00:00","date_gmt":"2016-11-07T07:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-keytruda-pembrolizumab-data-accepted-for-presentation-at-sitc-2016-annual-meeting\/"},"modified":"2025-11-07T01:25:33","modified_gmt":"2025-11-07T06:25:33","slug":"new-keytruda-pembrolizumab-data-accepted-for-presentation-at-sitc-2016-annual-meeting","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-keytruda-pembrolizumab-data-accepted-for-presentation-at-sitc-2016-annual-meeting\/","title":{"rendered":"New KEYTRUDA\u00ae (pembrolizumab) Data Accepted for Presentation at SITC 2016 Annual Meeting"},"content":{"rendered":"<p class=\"bwalignc\">       First Presentation of Overall Survival Data in Patients with Advanced        Bladder (Urothelial) Cancer from KEYNOTE-045 Study     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that new data investigating the use of KEYTRUDA<sup>\u00ae<\/sup><br \/>\n      (pembrolizumab), the company\u2019s anti-PD-1 therapy, in patients with<br \/>\n      previously treated advanced urothelial cancer will be presented at the<br \/>\n      Society for Immunotherapy of Cancer\u2019s (SITC) 31<sup>st<\/sup> Annual<br \/>\n      Meeting, Nov. 9-13. Data on overall survival (OS) and progression-free<br \/>\n      survival (PFS) from the phase 3 KEYNOTE-045 study \u2013 investigating<br \/>\n      KEYTRUDA compared to investigator\u2019s choice chemotherapy in patients with<br \/>\n      metastatic or locally advanced or unresectable urothelial cancer that<br \/>\n      has recurred or progressed following platinum-based chemotherapy \u2013 will<br \/>\n      be presented for the first time; these data were accepted as a<br \/>\n      late-breaking abstract. In addition, results from three different<br \/>\n      studies exploring the utility of various biomarkers for KEYTRUDA will be<br \/>\n      presented at the meeting.\n    <\/p>\n<p>\n      <b>KEYTRUDA Data at SITC 2016<\/b>\n    <\/p>\n<p>\n      Below is a select listing of the KEYTRUDA abstracts accepted at SITC<br \/>\n      2016; abstracts are available on the <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.eventscribe.com%2F2016%2FSITC%2F&amp;esheet=51454962&amp;newsitemid=20161107005380&amp;lan=en-US&amp;anchor=meeting+website&amp;index=1&amp;md5=28a919c490393bd422c1cef824c75276\" rel=\"nofollow\"><br \/>\n<b>meeting<br \/>\n      website<\/b><br \/>\n<\/a>.\n    <\/p>\n<p>\n      <b>Late-Breaking Oral Presentation, Location: <\/b>Maryland Ballroom\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        (Abstract #470) KEYNOTE-045: open-label, phase 3 study of<br \/>\n        pembrolizumab versus investigator\u2019s choice of paclitaxel, docetaxel,<br \/>\n        or vinflunine for previously treated advanced urothelial cancer.<br \/>\n<b>Session<br \/>\n        Time:<\/b> Saturday, Nov. 12, 11:15 a.m. \u2013 12:00 p.m. ET<br \/>\n<b>Presentation<br \/>\n        Time:<\/b> 11:45 a.m. \u2013 12:00 p.m. ET\n      <\/li>\n<\/ul>\n<p>\n      <b>Poster Presentations, Location: <\/b>Prince George&#8217;s Exhibition Hall AB\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        (Abstract #61) Association between microsatellite instability and<br \/>\n        clinical response across tumor types in the phase 1b KEYNOTE-012 and<br \/>\n        KEYNOTE-028 studies of pembrolizumab in PD-L1-expressing advanced<br \/>\n        solid tumors.<br \/>\n<b>Session Time:<\/b> Friday, Nov. 11, 12:15 p.m. \u2013<br \/>\n        1:30 p.m. ET\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        (Abstract #72) An immune-related gene expression profile delineates<br \/>\n        features of the tumor microenvironment required for clinical response<br \/>\n        to PD-1 blockade.<br \/>\n<b>Session Time: <\/b>Saturday, Nov. 12, 11:45<br \/>\n        a.m. \u2013 1:00 p.m. ET\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        (Abstract #73) Tumor mutational load and T cell inflamed<br \/>\n        microenvironment are independent determinants of response to<br \/>\n        pembrolizumab.<br \/>\n<b>Session Time:<\/b> Friday, Nov. 11, 12:15 p.m. \u2013<br \/>\n        1:30 p.m. ET\n      <\/li>\n<\/ul>\n<p>\n      The KEYTRUDA (pembrolizumab) clinical development program includes more<br \/>\n      than 30 tumor types in more than 360 clinical trials, including nearly<br \/>\n      200 trials that combine KEYTRUDA with other cancer treatments. For<br \/>\n      genitourinary cancers, Merck has the largest immuno-oncology clinical<br \/>\n      development program in bladder cancer, with 27 trials underway involving<br \/>\n      KEYTRUDA as monotherapy and in combination, including four<br \/>\n      registration-enabling studies.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is a humanized monoclonal antibody that works by increasing the<br \/>\n      ability of the body\u2019s immune system to help detect and fight tumor<br \/>\n      cells. KEYTRUDA blocks the interaction between PD-1 and its ligands,<br \/>\n      PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both<br \/>\n      tumor cells and healthy cells.\n    <\/p>\n<p>\n      KEYTRUDA is administered as an intravenous infusion over 30 minutes<br \/>\n      every three weeks for the approved indications. KEYTRUDA for injection<br \/>\n      is supplied in a 100 mg single use vial.\n    <\/p>\n<p>\n      <b>KEYTRUDA<\/b> <b>Indications and Dosing<\/b>\n    <\/p>\n<p>\n      <i>Melanoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) is indicated for the treatment of patients with<br \/>\n      unresectable or metastatic melanoma at a dose of 2 mg\/kg every three<br \/>\n      weeks until disease progression or unacceptable toxicity.\n    <\/p>\n<p>\n      <i>Lung Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the first-line treatment of patients with<br \/>\n      metastatic non-small cell lung cancer (NSCLC) whose tumors have high<br \/>\n      PD-L1 expression [tumor proportion score (TPS) \u226550%] as determined by an<br \/>\n      FDA-approved test, with no EGFR or ALK genomic tumor aberrations.\n    <\/p>\n<p>\n      KEYTRUDA is also indicated for the treatment of patients with metastatic<br \/>\n      NSCLC whose tumors express PD-L1 (TPS \u22651%) as determined by an<br \/>\n      FDA-approved test, with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA.\n    <\/p>\n<p>\n      In metastatic NSCLC, KEYTRUDA is administered at a fixed dose of 200 mg<br \/>\n      every three weeks until disease progression, unacceptable toxicity, or<br \/>\n      up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      <i>Head and Neck Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic head and neck squamous cell carcinoma (HNSCC) with disease<br \/>\n      progression on or after platinum-containing chemotherapy. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. In HNSCC, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression, unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup>&nbsp;<b>(pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated pneumonitis, including fatal cases.<br \/>\n      Pneumonitis occurred in 94 (3.4%) of 2799 patients receiving KEYTRUDA,<br \/>\n      including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4 (0.3%), and 5 (0.1%)<br \/>\n      pneumonitis, and occurred more frequently in patients with a history of<br \/>\n      prior thoracic radiation (6.9%) compared to those without (2.9%).<br \/>\n      Monitor patients for signs and symptoms of pneumonitis. Evaluate<br \/>\n      suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      (pembrolizumab) for Grade 2; permanently discontinue KEYTRUDA for Grade<br \/>\n      3 or 4 or recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 48<br \/>\n      (1.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.4%), 3<br \/>\n      (1.1%), and 4 (&lt;0.1%) colitis. Monitor patients for signs and symptoms<br \/>\n      of colitis. Administer corticosteroids for Grade 2 or greater colitis.<br \/>\n      Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 colitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred in 19<br \/>\n      (0.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.4%), and 4 (&lt;0.1%) hepatitis. Monitor patients for changes in liver<br \/>\n      function. Administer corticosteroids for Grade 2 or greater hepatitis<br \/>\n      and, based on severity of liver enzyme elevations, withhold or<br \/>\n      discontinue KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA can cause hypophysitis. Hypophysitis occurred in 17 (0.6%) of<br \/>\n      2799 patients receiving KEYTRUDA, including Grade 2 (0.2%), 3 (0.3%),<br \/>\n      and 4 (&lt;0.1%) hypophysitis. Monitor patients for signs and symptoms of<br \/>\n      hypophysitis (including hypopituitarism and adrenal insufficiency).<br \/>\n      Administer corticosteroids and hormone replacement as clinically<br \/>\n      indicated. Withhold KEYTRUDA for Grade 2; withhold or discontinue for<br \/>\n      Grade 3 or 4 hypophysitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause thyroid disorders, including hyperthyroidism,<br \/>\n      hypothyroidism, and thyroiditis. Hyperthyroidism occurred in 96 (3.4%)<br \/>\n      of 2799 patients receiving KEYTRUDA, including Grade 2 (0.8%) and 3<br \/>\n      (0.1%) hyperthyroidism. Hypothyroidism occurred in 237 (8.5%) of 2799<br \/>\n      patients receiving KEYTRUDA, including Grade 2 (6.2%) and 3 (0.1%)<br \/>\n      hypothyroidism. The incidence of new or worsening hypothyroidism was<br \/>\n      higher in patients with HNSCC occurring in 28 (15%) of 192 patients with<br \/>\n      HNSCC, including Grade 3 (0.5%) hypothyroidism. Thyroiditis occurred in<br \/>\n      16 (0.6%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.3%)<br \/>\n      thyroiditis. Monitor patients for changes in thyroid function (at the<br \/>\n      start of treatment, periodically during treatment, and as indicated<br \/>\n      based on clinical evaluation) and for clinical signs and symptoms of<br \/>\n      thyroid disorders. Administer replacement hormones for hypothyroidism<br \/>\n      and manage hyperthyroidism with thionamides and beta-blockers as<br \/>\n      appropriate. Withhold or discontinue KEYTRUDA for Grade 3 or 4<br \/>\n      hyperthyroidism.\n    <\/p>\n<p>\n      KEYTRUDA can cause type 1 diabetes mellitus, including diabetic<br \/>\n      ketoacidosis, which have been reported in 6 (0.2%) of 2799 patients.<br \/>\n      Monitor patients for hyperglycemia or other signs and symptoms of<br \/>\n      diabetes. Administer insulin for type 1 diabetes, and withhold KEYTRUDA<br \/>\n      and administer antihyperglycemics in patients with severe hyperglycemia.\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) can cause immune-mediated nephritis. Nephritis<br \/>\n      occurred in 9 (0.3%) of 2799 patients receiving KEYTRUDA, including<br \/>\n      Grade 2 (0.1%), 3 (0.1%), and 4 (&lt;0.1%) nephritis. Monitor patients for<br \/>\n      changes in renal function. Administer corticosteroids for Grade 2 or<br \/>\n      greater nephritis. Withhold KEYTRUDA for Grade 2; permanently<br \/>\n      discontinue KEYTRUDA for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      KEYTRUDA can cause other clinically important immune-mediated adverse<br \/>\n      reactions. For suspected immune-mediated adverse reactions, ensure<br \/>\n      adequate evaluation to confirm etiology or exclude other causes. Based<br \/>\n      on the severity of the adverse reaction, withhold KEYTRUDA and<br \/>\n      administer corticosteroids. Upon improvement to Grade 1 or less,<br \/>\n      initiate corticosteroid taper and continue to taper over at least 1<br \/>\n      month. Based on limited data from clinical studies in patients whose<br \/>\n      immune-related adverse reactions could not be controlled with<br \/>\n      corticosteroid use, administration of other systemic immunosuppressants<br \/>\n      can be considered. Resume KEYTRUDA when the adverse reaction remains at<br \/>\n      Grade 1 or less following corticosteroid taper. Permanently discontinue<br \/>\n      KEYTRUDA for any Grade 3 immune-mediated adverse reaction that recurs<br \/>\n      and for any life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 2799 patients:<br \/>\n      arthritis (1.5%), exfoliative dermatitis, bullous pemphigoid, rash<br \/>\n      (1.4%), uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia gravis,<br \/>\n      vasculitis, pancreatitis, hemolytic anemia, and partial seizures arising<br \/>\n      in a patient with inflammatory foci in brain parenchyma.\n    <\/p>\n<p>\n      KEYTRUDA can cause severe or life-threatening infusion-related<br \/>\n      reactions, which have been reported in 6 (0.2%) of 2799 patients.<br \/>\n      Monitor patients for signs and symptoms of infusion-related reactions,<br \/>\n      including rigors, chills, wheezing, pruritus, flushing, rash,<br \/>\n      hypotension, hypoxemia, and fever. For Grade 3 or 4 reactions, stop<br \/>\n      infusion and permanently discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      In KEYNOTE-006, KEYTRUDA was discontinued due to adverse reactions in 9%<br \/>\n      of 555 patients with advanced melanoma; adverse reactions leading to<br \/>\n      discontinuation in more than one patient were colitis (1.4%), autoimmune<br \/>\n      hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy (0.4%), and<br \/>\n      cardiac failure (0.4%). Adverse reactions leading to interruption of<br \/>\n      KEYTRUDA (pembrolizumab) occurred in 21% of patients; the most common<br \/>\n      (\u22651%) was diarrhea (2.5%). The most common adverse reactions with<br \/>\n      KEYTRUDA vs ipilimumab were fatigue (28% vs 28%), diarrhea (26% with<br \/>\n      KEYTRUDA), rash (24% vs 23%), and nausea (21% with KEYTRUDA).<br \/>\n      Corresponding incidence rates are listed for ipilimumab only for those<br \/>\n      adverse reactions that occurred at the same or lower rate than with<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      In KEYNOTE-002, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      12% of 357 patients with advanced melanoma; the most common (\u22651%) were<br \/>\n      general physical health deterioration (1%), asthenia (1%), dyspnea (1%),<br \/>\n      pneumonitis (1%), and generalized edema (1%). Adverse reactions leading<br \/>\n      to interruption of KEYTRUDA occurred in 14% of patients; the most common<br \/>\n      (\u22651%) were dyspnea (1%), diarrhea (1%), and maculopapular rash (1%). The<br \/>\n      most common adverse reactions with KEYTRUDA vs chemotherapy were fatigue<br \/>\n      (43% with KEYTRUDA), pruritus (28% vs 8%), rash (24% vs 8%),<br \/>\n      constipation (22% vs 20%), nausea (22% with KEYTRUDA), diarrhea (20% vs<br \/>\n      20%), and decreased appetite (20% with KEYTRUDA). Corresponding<br \/>\n      incidence rates are listed for chemotherapy only for those adverse<br \/>\n      reactions that occurred at the same or lower rate than with KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA was discontinued due to adverse reactions in 8% of 682 patients<br \/>\n      with metastatic NSCLC. The most common adverse event resulting in<br \/>\n      permanent discontinuation of KEYTRUDA was pneumonitis (1.8%). Adverse<br \/>\n      reactions leading to interruption of KEYTRUDA occurred in 23% of<br \/>\n      patients; the most common (\u22651%) were diarrhea (1%), fatigue (1.3%),<br \/>\n      pneumonia (1%), liver enzyme elevation (1.2%), decreased appetite<br \/>\n      (1.3%), and pneumonitis (1%). The most common adverse reactions<br \/>\n      (occurring in at least 20% of patients and at a higher incidence than<br \/>\n      with docetaxel) were decreased appetite (25% vs 23%), dyspnea (23% vs<br \/>\n      20%), and nausea (20% vs 18%).\n    <\/p>\n<p>\n      KEYTRUDA was discontinued due to adverse reactions in 17% of 192<br \/>\n      patients with HNSCC. Serious adverse reactions occurred in 45% of<br \/>\n      patients. The most frequent serious adverse reactions reported in at<br \/>\n      least 2% of patients were pneumonia, dyspnea, confusional state,<br \/>\n      vomiting, pleural effusion, and respiratory failure. The most common<br \/>\n      adverse reactions (reported in at least 20% of patients) were fatigue,<br \/>\n      decreased appetite, and dyspnea. Adverse reactions occurring in patients<br \/>\n      with HNSCC were generally similar to those occurring in patients with<br \/>\n      melanoma or NSCLC, with the exception of increased incidences of facial<br \/>\n      edema (10% all Grades; 2.1% Grades 3 or 4) and new or worsening<br \/>\n      hypothyroidism.\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA (pembrolizumab) is excreted in human<br \/>\n      milk. Because many drugs are excreted in human milk, instruct women to<br \/>\n      discontinue nursing during treatment with KEYTRUDA and for 4 months<br \/>\n      after the final dose.\n    <\/p>\n<p>\n      Safety and effectiveness of KEYTRUDA have not been established in<br \/>\n      pediatric patients.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, helping people<br \/>\n      fight cancer is our passion and supporting accessibility to our cancer<br \/>\n      medicines is our commitment. Our focus is on pursuing research in<br \/>\n      immuno-oncology and we are accelerating every step in the journey \u2013 from<br \/>\n      lab to clinic \u2013 to potentially bring new hope to people with cancer.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the fastest-growing development<br \/>\n      programs in the industry. We are currently executing an expansive<br \/>\n      research program that includes more than 360 clinical trials evaluating<br \/>\n      our anti-PD-1 therapy across more than 30 tumor types. We also continue<br \/>\n      to strengthen our immuno-oncology portfolio through strategic<br \/>\n      acquisitions and are prioritizing the development of several promising<br \/>\n      immunotherapeutic candidates with the potential to improve the treatment<br \/>\n      of advanced cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51454962&amp;newsitemid=20161107005380&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=2&amp;md5=94b2387b20538e67b64f0e25ca3fa8ff\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For 125 years, Merck has been a global health care leader working to<br \/>\n      help the world be well. Merck is known as MSD outside the United States<br \/>\n      and Canada. Through our prescription medicines, vaccines, biologic<br \/>\n      therapies, and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      health care through far-reaching policies, programs and partnerships.<br \/>\n      For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51454962&amp;newsitemid=20161107005380&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=3&amp;md5=5ba80454e85059cd0fe01e7f0b775bf6\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51454962&amp;newsitemid=20161107005380&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=0bab65ff41f137cf7b61adcbc82ced25\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51454962&amp;newsitemid=20161107005380&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=6c6de76ad7143b0adc26afbf6ae40375\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51454962&amp;newsitemid=20161107005380&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=1ada6db12356571d1cf6c97fcd967f20\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51454962&amp;newsitemid=20161107005380&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=7&amp;md5=933df703b48463549fbe7c3be39c39f1\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2015 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51454962&amp;newsitemid=20161107005380&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=8&amp;md5=0594cd0b5c470681e0fce69721a13f12\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51454962&amp;newsitemid=20161107005380&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=9&amp;md5=2fd7d2d61ec787138dc6edd211d5865c\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b>&nbsp;and<\/b>\n    <\/p>\n<p>\n      <b>Patient Information\/Medication Guide for KEYTRUDA at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51454962&amp;newsitemid=20161107005380&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=10&amp;md5=dad5f0c87cbaf9a3a3bdf7af0102856e\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20161107005380r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Kim        Hamilton, 908-740-1863<br \/>or<br \/>Investors:<br \/>Teri Loxam,        908-740-1986<br \/>or<br \/>Amy Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new data investigating the use of KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in patients with previously treated advanced urothelial cancer will be presented at the Society for Immunotherapy of Cancer\u2019s (SITC) 31 st Annual Meeting, Nov. 9-13. Data on overall survival (OS) and progression-free survival (PFS) from the phase 3 KEYNOTE-045 study \u2013 investigating KEYTRUDA compared to investigator\u2019s choice chemotherapy in patients with metastatic or locally advanced or unresectable urothelial cancer that has recurred or progressed following platinum-based chemotherapy \u2013 will be presented for the first time; these data were accepted as a late-breaking abstract. In addition, results from three different studies exploring the utility of various biomarkers for KEYTRUDA will be presented at the meeting. KEYTRUDA Data at SITC 2016 Below is a select listing of the KEYTRUDA abstracts accepted<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,55,289,56],"class_list":["post-745306","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-prescription-medicine-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>New KEYTRUDA\u00ae (pembrolizumab) Data Accepted for Presentation at SITC 2016 Annual Meeting - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-keytruda-pembrolizumab-data-accepted-for-presentation-at-sitc-2016-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New KEYTRUDA\u00ae (pembrolizumab) Data Accepted for Presentation at SITC 2016 Annual Meeting - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new data investigating the use of KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in patients with previously treated advanced urothelial cancer will be presented at the Society for Immunotherapy of Cancer\u2019s (SITC) 31 st Annual Meeting, Nov. 9-13. Data on overall survival (OS) and progression-free survival (PFS) from the phase 3 KEYNOTE-045 study \u2013 investigating KEYTRUDA compared to investigator\u2019s choice chemotherapy in patients with metastatic or locally advanced or unresectable urothelial cancer that has recurred or progressed following platinum-based chemotherapy \u2013 will be presented for the first time; these data were accepted as a late-breaking abstract. In addition, results from three different studies exploring the utility of various biomarkers for KEYTRUDA will be presented at the meeting. KEYTRUDA Data at SITC 2016 Below is a select listing of the KEYTRUDA abstracts accepted\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-keytruda-pembrolizumab-data-accepted-for-presentation-at-sitc-2016-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-keytruda-pembrolizumab-data-accepted-for-presentation-at-sitc-2016-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-keytruda-pembrolizumab-data-accepted-for-presentation-at-sitc-2016-annual-meeting\\\/\",\"name\":\"New KEYTRUDA\u00ae (pembrolizumab) Data Accepted for Presentation at SITC 2016 Annual Meeting - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2016-11-07T07:00:00+00:00\",\"dateModified\":\"2025-11-07T06:25:33+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-keytruda-pembrolizumab-data-accepted-for-presentation-at-sitc-2016-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-keytruda-pembrolizumab-data-accepted-for-presentation-at-sitc-2016-annual-meeting\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-keytruda-pembrolizumab-data-accepted-for-presentation-at-sitc-2016-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New KEYTRUDA\u00ae (pembrolizumab) Data Accepted for Presentation at SITC 2016 Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New KEYTRUDA\u00ae (pembrolizumab) Data Accepted for Presentation at SITC 2016 Annual Meeting - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-keytruda-pembrolizumab-data-accepted-for-presentation-at-sitc-2016-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"New KEYTRUDA\u00ae (pembrolizumab) Data Accepted for Presentation at SITC 2016 Annual Meeting - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new data investigating the use of KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in patients with previously treated advanced urothelial cancer will be presented at the Society for Immunotherapy of Cancer\u2019s (SITC) 31 st Annual Meeting, Nov. 9-13. Data on overall survival (OS) and progression-free survival (PFS) from the phase 3 KEYNOTE-045 study \u2013 investigating KEYTRUDA compared to investigator\u2019s choice chemotherapy in patients with metastatic or locally advanced or unresectable urothelial cancer that has recurred or progressed following platinum-based chemotherapy \u2013 will be presented for the first time; these data were accepted as a late-breaking abstract. In addition, results from three different studies exploring the utility of various biomarkers for KEYTRUDA will be presented at the meeting. KEYTRUDA Data at SITC 2016 Below is a select listing of the KEYTRUDA abstracts accepted","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-keytruda-pembrolizumab-data-accepted-for-presentation-at-sitc-2016-annual-meeting\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:33+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-keytruda-pembrolizumab-data-accepted-for-presentation-at-sitc-2016-annual-meeting\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-keytruda-pembrolizumab-data-accepted-for-presentation-at-sitc-2016-annual-meeting\/","name":"New KEYTRUDA\u00ae (pembrolizumab) Data Accepted for Presentation at SITC 2016 Annual Meeting - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2016-11-07T07:00:00+00:00","dateModified":"2025-11-07T06:25:33+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-keytruda-pembrolizumab-data-accepted-for-presentation-at-sitc-2016-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-keytruda-pembrolizumab-data-accepted-for-presentation-at-sitc-2016-annual-meeting\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-keytruda-pembrolizumab-data-accepted-for-presentation-at-sitc-2016-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"New KEYTRUDA\u00ae (pembrolizumab) Data Accepted for Presentation at SITC 2016 Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"f5cd132d-3289-4220-b089-5e70d0794f0d","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/New-KEYTRUDA-pembrolizumab-Data-Accepted-for-Presentation-at-SITC-2016-Annual-Meeting-2016.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745306","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745306\/revisions"}],"predecessor-version":[{"id":3674715,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745306\/revisions\/3674715"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745306"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745306"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}